Outcomes of a drug shortage requiring switching in patients with ulcerative colitis

doi:10.4291/wjgp.v11.i2.32

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7154)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

333

WORD

226

HTML

3829

Figures (1-4)

432

Tables (1-2)

391

Sum=5211

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

765

Download

1178

Sum=1943

Apr 12, 2020 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pathophysiology

ISSN

2150-5330

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Pathophysiol. Apr 12, 2020; 11(2): 32-42
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32

Full Size Figure Download Figure

Figure 2 Flow chart depicting the switch to alternative aminosalicylate resulting from the balsalazide shortage, with adverse effect rate of 35. 5% occurring immediately post-switch, which in all cases resolved upon return to balsalazide.

Citation: van Langenberg DR, Cheng RKY, Garg M. Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. World J Gastrointest Pathophysiol 2020; 11(2): 32-42
URL: https://www.wjgnet.com/2150-5330/full/v11/i2/32.htm
DOI: https://dx.doi.org/10.4291/wjgp.v11.i2.32